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Limb-girdle muscular dystrophy (LGMD) 2L, caused by mutations in the anoctamin 5 (ANO5) gene, is the third most common
LGMD in Northern and Central Europe, where the c.191dupA mutation causes the majority of cases. We evaluated data from 228
Italian LGMD patients to determine the prevalence of LGMD2L and the c.191dupA mutation, and to describe the clinical, muscle
biopsy, and magnetic resonance imaging ﬁndings in these patients. Forty-three patients who lacked molecular diagnosis were studied
for ANO5 mutations, and four novel mutations were found in three probands. Only one proband carried the c.191dupA mutation,
which was compound heterozygous with c.2516T>G. Two probands were homozygous for the c.1627dupA and c.397A>T mutations,
respectively, while a fourth proband had a compound heterozygous status (c.220C>T and c.1609T>C). Therefore occurrence and
molecular epidemiology of LGMD2L in this Italian cohort diﬀered from those observed in other European countries. ANO5 mutations
accounted for 2% of our sample. Aﬀected patients exhibited benign progression with variable onset and an absence of cardiac and
respiratory impairment; muscle biopsy generally showed mild signs, except when performed on the quadriceps muscles; MRI showed
predominant involvement of the posterior thigh. Overall these common clinical, morphological and imaging ﬁndings could be useful
in diﬀerential diagnosis.
 2012 Elsevier B.V.
Keywords: Limb girdle muscular dystrophy 2L; Quadriceps myopathy; Anoctamin 5; Chloride channel; Membrane repair
Open access under CC BY-NC-ND license.1. Introduction
Limb-girdle muscular dystrophy (LGMD) 2L is a reces-
sive form of LGMD described for the ﬁrst time in 2010 [1].0960-8966  2012 Elsevier B.V.
http://dx.doi.org/10.1016/j.nmd.2012.05.001
⇑ Corresponding author. Adderess: Dipartimento di Scienze Neurolog-
iche, Universita` di Milano, Padiglione Ponti, Ospedale Maggiore Policli-
nico, Via Francesco Sforza 35, 20122 Milan, Italy. Tel.: +39 02 55033817;
fax: +39 02 50320430.
E-mail address: giacomo.comi@unimi.it (G.P. Comi).
Open access under CC BY-NC-ND license.The disease is caused by mutations in the anoctamin 5
(ANO5) gene, which contains 22 exons and maps to chro-
mosome 11. Recessive mutations in this gene have also
been reported to cause a distal non-dysferlin Miyoshi-like
myopathy (MM3) [2], whereas dominant variations can
determine gnathodiaphyseal dysplasia (GDD) [3].
Anoctamin 5 is a member of the anoctamin family,
which comprises at least ten proteins, each consisting of
eight transmembrane domains and a DUF590 domain of
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and reportedly act as calcium-activated chloride channels.
In particular, anoctamin 5 is expressed in skeletal muscle
and the heart, where it is localised in intracellular vesicles
and the endoplasmic reticulum [5] and seems to participate
in membrane repair [6].
The existence of a novel autosomal recessive LGMD
was suggested in 2007 by Jarry et al. [7]; in a cohort of
French Canadian families, they described a form with
prominent asymmetrical atrophy of the quadriceps femoris
and biceps brachii that seemed to map to chromosome
11p13-p12. Three years later, a study with a larger sample
of patients better deﬁned the involved region as 11p14.3-
p15, leading to the identiﬁcation of ANO5 as the responsi-
ble gene [1]. Thus far, other cases have been described in
populations from Northern England, Finland, Germany
and France [2,8–12]. This form seems to be the third most
common form of LGMD in Northern England [8] behind
LGMD2A and LGMD2I. Overall, 49 families and 19 dif-
ferent mutations have been described in the literature,
without hot-spots along the gene although the 60% of
mutations occur in the 50 portion of the gene (between exon
15 and 20). The c.191dupA mutation is responsible for the
majority of cases; it was described as homozygous in 14
families and as compound heterozygous with another
mutation in 16 families, suggesting a founder eﬀect in
Northern Europe populations [8]. The c.2272C>T is partic-
ularly frequent in Finnish population, since it was found in
20 independent families. Among the other 17 mutations
that were detected, the c.1407+5G>A substitution was
reported three times, the c.1295C>G, c.172C>T,
c.2018A>G, c.692G>T mutations twice, and the remaining
mutations only once (Fig. 1A). All patients show some
common clinical aspects, namely predominant lower limb
involvement with impairment of the posterior compart-Fig. 1. Schematic representation of the intron/exon organisation of ANO5 and
in the literature. In the box, the mutations that are reported more than on
compound heterozygous mutations in blue, and heterozygous mutations in grment muscles, mild to signiﬁcant increase in creatine kinase
(CK), adulthood onset, slow progression, and absence of
cardiac and respiratory involvement [8].
However, all of these data are based on the analysis of a
small sample of patients limited to Northern Europe. Fur-
ther studies are needed to analyse the prevalence of this
muscular dystrophy in other countries and to better deﬁne
both the clinical presentation and prognostic factors. Here,
we report a study of an Italian sample of 228 LGMD
patients in order to establish the prevalence of LGMD2L
in Italy and to better deﬁne the clinical, morphological,
and molecular features of this form.2. Materials and methods
2.1. Patient selection
We selected 43 LGMD patients (37 families) without a
molecular diagnosis from a cohort of 228 LGMD patients
from 190 families that was previously examined at our neu-
romuscular clinic. The 153 remaining probands had a
molecularly proven diagnosis of LGMD, distributed as fol-
lows: 59 LGMD2A, 42 LGMD2B, 9 LGMD2C, 16
LGMD2D, 8 LGMD2E, 1 LGMD2F, 14 LGMD2I, and
3 LGMD1C. Patients were deﬁned as aﬀected with LGMD
if they fulﬁlled the following criteria: a clinical phenotype
characterised by progressive muscle weakness and wasting
aﬀecting primarily the shoulder girdle and pelvic muscles,
keeping with the diagnostic criteria for LGMD [13], and
dystrophic features at muscle biopsy. Patients had all
undergone a systematic clinical characterisation, including
comprehensive neurological, cardiac (electrocardiogram
and echocardiogram), and respiratory (spirometry)
assessments. Muscle imaging data were also obtained by
nuclear magnetic resonance imaging (MRI) or computeddistribution of mutations along the gene. (A) Mutations already described
ce are highlighted. (B) Mutations found in our cohort. Homozygous or
een.
936 F. Magri et al. / Neuromuscular Disorders 22 (2012) 934–943tomography (CT) when available. All specimens were
obtained from the “DNA, Muscle and Nerve Tissue Bank”
of the Neurological Unit, Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, University of Milan.
Written informed consent was obtained from all subjects
or their caregivers when primary diagnostic procedures
were performed, with explicit consent for future use for
research purposes, according to the Declaration of Hel-
sinki. This protocol was approved by the Institutional
Review Board. Overall, 90% of patients were from Italian
families; the remaining subjects were from other countries
(Switzerland, Tunisia, and Albania). These latter patients
were not considered in the evaluation of the population-
based proportion of LGMDs.
2.2. Muscle tissue analysis
All probands underwent muscle biopsy of the brachial
biceps or quadriceps femorii muscles. Morphological
examination was performed following standardised meth-
ods. We studied the most important proteins involved in
LGMDs using immunohistochemical (IHC) analyses with
monoclonal antibodies directed against dystrophin (Novo-
castra, Newcastle upon Tyne, UK) [14], sarcoglycans, dys-
ferlin (Novocastra), a-dystroglycan (a-DG) (Upstate
Biotechnology, Lake Placid, NY), and caveolin-3 (Trans-
duction Laboratories, Lexington, KY) as described previ-
ously [15,16]. The protein defects uncovered by IHC
analysis were conﬁrmed by Western blotting using the
same monoclonal antibodies. This technique was also used
for the calpain-3 screening using the Novocastra monoclo-
nal antibody Calp 3d/2C4 [17]. For electron microscopy
(EM) studies, muscle samples were ﬁxed in glutaraldehyde
and processed using standard procedures [18].
2.3. Molecular analysis
Genomic DNA was extracted from peripheral blood
samples according to standard procedures (Flexi Gene
DNA Handbook, Qiagen). All patients were screened for
the c.191dupA mutation, which is commonly found in Eng-
lish and German populations, by direct sequencing of the
PCR products using an ABI PRISM 3100 XL Genetic
Analyzer (Applied Biosystems). In patients without muta-
tions, we used the same method to analyse all 22 ANO5
exons and their ﬂanking intronic regions. Primer sequences
and PCR conditions are available upon request.
The pathogenic nature of new mutations was conﬁrmed
by screening 160 healthy control subjects, and the parental
origin of each mutation was assessed from the parental
genomic DNA when available. Amino acid conservation
was conﬁrmed by comparing sequences in diﬀerent species.
For some patients, mRNA was isolated from muscle tissue
using Eurozol. cDNA was produced through reverse tran-
scription polymerase chain reaction (RT-PCR) using the
Ready-To-Go RT-PCR kit (Amersham Pharmacia) and
analysed by mRNA ampliﬁcation and sequencing.Mutations were named according to the Leiden Muscu-
lar Dystrophy database (www.dmd.nl). For cDNA num-
bering, +1 corresponds to the A of the ATG translation
initiation codon in the reference sequence.3. Results
We studied ANO5 in 43 patients (37 families) aﬀected
with LGMD but lacking a molecular diagnosis. Homozy-
gous or compound heterozygous causative mutations were
found in four probands (six patients). Only one patient car-
ried the heterozygous c.191dupA mutation that was com-
mon in previous studies. Four novel mutations were
detected (Fig. 1).
The molecular and clinical features of the patients are
summarised in Tables 1 and 2.
Two probands (three patients) carried single heterozy-
gous mutations. They were characterised by more hetero-
geneous clinical presentations.3.1. Patient I
Patient I was a 47-year-old man delivered after a regular
pregnancy, with normal psychomotor development and
negative family history (Fig. 2A). During childhood and
adulthood the patient played soccer at a competitive level.
In early adulthood, altered liver enzyme values had been
found but never investigated. At 31 years of age the patient
experienced an episode of myoglobinuria with high CK lev-
els (10,000 UI/L). Since that time, the disease showed a
progressive course with onset of mild weakness of the lower
limbs starting at 36 years of age, and diﬃculties climbing
stairs and rising from a chair at 40 years of age. CK levels
were moderately increased (6- to 11-fold above normal).
Electromyography showed myopathic changes.
The patient underwent two muscle biopsies. The ﬁrst
biopsy, performed at 31 years of age on the quadriceps
femorii, revealed a severe dystrophic pattern with nuclear
centralisation and increased connective tissue. The second
biopsy, performed at the age of 46 years on the brachial
biceps, showed a milder pattern with some central nuclei
and necrotic ﬁbres, but no increase in connective tissue.
Dystrophin immunostaining and Western blot results were
normal. We found a mild reduction in the 30-kD calpain-3
band, but molecular analysis of calpain-3 did not reveal any
mutations. An ultrastructural study demonstrated basal
lamina duplication (data not shown) and focal loss of the
plasma membrane with sporadic thickening of the basal
lamina overlying the plasma membrane defect (Fig. 3C
and D).
Neurological examination showed a predominant lower
limb involvement, including severe asymmetric muscle
atrophy of the quadriceps and posterior compartment of
the leg (Fig. 4A) with selective quadriceps and hamstring
weakness. Upper limb muscle bulk and strength were nor-
mal. Cardiac and respiratory involvement was absent.
Fig. 2. Pedigrees of the mutated families. Familiars that were tested for ANO5 mutations are speciﬁed in each pedigree. WT: wild-type.
Table 2
Clinical characteristics of LGMD2L patients.
Pt Age
(yrs)
Gender Onset
(yrs)
Clinical
features
Symptoms
at onset
Atrophy
distribution
Muscle
weakness
CH C My Mg Cardiac
involvement
Respiratory
involvement
EMG CPK Clinical
evolution
I 47 M 39 LGMD (lower limbs) Myoglobinuria Quadriceps,
posterior
compartment
Quadriceps
and biceps
femorii
– – – + None None Myopatic 6–11x Slow
II.1 51 M 15 LGMD + distal
involvement
Mild weakness Harmstrings,
quadriceps
Quadriceps,
biceps femorii
+ + + – None None Myopatic 5–32x Slow
II.2 43 M 33 LGMD (almost
asymptomatic,
mainly
lower limbs)
Asymptomatic
hyperCKemia
Harmstrings,
quadriceps
Biceps femorii ++ – – + None None Myopatic 15–31x Slow
III.1 45 M 28 LGMD (lower limbs Fatigability
and cramps
Quadriceps Quadriceps + + + Nd None None Myopatic 16x Slow
III.2 47 F Nd HyperCKemia None None None – – – – None None Not
performed
3x Nd
IV 50 M 47 LGMD (four limbs) Myalgias and
hyposthenia
Asymmetric
quadriceps
Quadriceps – + + + None None Myopatic 2–7x Slow
CH: calf pseudohypertrophy, C: cramps; My: myalgia; Mg: myoglobinuria.
Table 1
ANO5 gene mutations in our cohort.
Allele 1 Allele 2
Pt Nucleotide Protein Exon Reference Nucleotide Protein Exon Reference
I c.220C>T p.Arg74X 5 New c.1609T>C p.Ser537Pro 15 New
II.1 c.1627dupA p.Met543AsnfsX10 15 Penttila (2012) c.1627dupA p.Met543Asnfs X10 15 Penttila (2012)
II.2 c.1627dupA p.Met543AsnfsX10 15 Penttila (2012) c.1627dupA p.Met543Asnfs X10 15 Penttila (2012)
III.1 c.191dupA p.Asn64LysfsX15 5 Brais (2010) c.2516T>G p.Met839Arg 21 New
III.2 c.191dupA p.Asn64LysfsX15 5 Brais (2010) c.2516T>G p.Met839Arg 21 New
IV c.397A>T p.Ile133Phe 7 New c.397A>T p.Ile133Phe 7 New
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subjected to several muscle imaging studies, both with MRIand CT scan. These studies clearly underlined the progres-
sion of the disease. The ﬁrst CT scan, performed at 29 years
Fig. 3. Muscle biopsy. (A and B) Light microscopy histology (250X) with Gomori’s Trichrome. Patient II.2: skeletal muscle ﬁbres show some centrally
located nuclei, and the connective tissue is slightly increased (A). Patient IV: skeletal muscle shows polygonal ﬁbres with a moderate increase in the central
nuclei and slight ﬁbre size variability (B). (C–F) Electron microscopy demonstrates defects in the plasma membranes and basal lamina in non-necrotic
muscle ﬁbres with focal loss of plasma membranes in (C) (30,000 X; higher magniﬁcation in the box) and (D) (25,000 X). Basal lamina overlying the
plasma membrane defects is normal in (C), but it is altered in (D) with thickened and ﬂocculent aspects. The basal lamina is replicated, forming more
layers in (E) and (F) (12,000 X).
Fig. 4. Clinical aspects (A) Patient I: vastus medial hamstrings and calf atrophy. (B) Patient II.1: mild sural hypertrophy and atrophy of the posterior
compartment of the thigh. (C) Patient II.2: marked sural hypertrophy with mild atrophy of the hamstrings. (D) Patient IV: severe asymmetric quadriceps
and posterior compartment atrophy.
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sive involvement of the gastrocnemius and soleus muscles
became evident over the years (latest study at 43 years of
age). The sartorius, semitendinous muscles, and the ante-
rior compartment of the leg were preserved (Fig. 5), with
exception of the quadriceps muscles, which were involved
with a patchy pattern. The involved muscles showed mild
hypodensity at the beginning of the illness (Fig. 5A andB) with progressive substitution of fatty tissue occurring
over the years (Fig. 5C and D).
Molecular analysis of ANO5 revealed the presence of
two heterozygous mutations (Fig. 6A). The ﬁrst mutation
(c.220C>T; p.Arg74X in exon 5) was a nonsense mutation
located in the N-terminal intracytoplasmic loop of the pro-
tein. The second mutation (c.1609T>C; p.Ser537Pro in
exon 15) was a missense mutation in a highly conserved
F. Magri et al. / Neuromuscular Disorders 22 (2012) 934–943 939portion of the gene, aﬀecting the loop between transmem-
brane domains 4 and 5 (Fig. 6E).
3.2. Patients II.1 and II.2
Patients II.1 and II.2 were brothers born from consan-
guineous parents. They had three siblings without muscu-
lar impairment (Fig. 2B). The older brother (patient II.1)
was a 51-year-old man with normal physical development;
in childhood and early adulthood he had participated in
martial arts at a competitive level. At 36 years of age,
patient II.1 was diagnosed with HIV and started antiretro-
viral therapy without relevant side eﬀects. At 39 years old,
the patient complained of weakness in his lower limbs with
diﬃculty in walking for long stretches. He underwent a
muscle biopsy of the brachial biceps, which showed mild
dystrophic and inﬂammatory signs, and was treated for
7 years with steroid therapy with only mild beneﬁt. CK lev-
els were consistently elevated at onset (32-fold) and mildly
increased in the following evaluations (5-fold).
Patient II.2 was a 43-year-old man who sought medical
attention at 31 years of age due to an incidental ﬁnding of
asymptomatic hyperCKemia (7000 UI/L). Two years later,
the patient started to complain of mild proximal weakness
in all four limbs, though he currently works as a tire
repairer. The patient experienced one episode of myoglobi-
nuria. At the age of 31 years, patient II.2 underwent muscle
biopsy of the biceps brachii, which showed a mild increase
in connective tissue, nuclear centralisation, and ﬁbre split-
ting (Fig. 3A).Fig. 5. Muscle imaging. (A–D) Muscle CT imaging of patient I at 29 years of a
only mild atrophy of the biceps femoris, whereas during the following years pro
muscles was observed. (E and F) MRI of the muscle of patient II.2, demonstrat
with partial atrophy of the quadriceps.Molecular analysis showed that both brothers had
homozygous single nucleotide duplication (c.1627dupA)
in exon 15 that disrupted the transcript reading frame
(p.Met543AsnfsX10) (Fig. 6B). Similar to the mutation in
patient I, this mutation is located in the intracytoplasmic
loop between transmembrane domains 4 and 5 (Fig. 6E).
Interestingly, neurological examination showed that
both brothers (Fig. 4B and C) had asymmetrical calf pseu-
dohypertrophy, though it was more marked in patient II.2,
and hamstring atrophy and weakness (score of 3 on the
Medical Research Council (MRC) scale in patient II.1
and 4 in patient II.2). Patient II.1 also showed quadriceps
weakness (score of 3 on the MRC scale) and mild upper
girdle involvement (4 on the MRC scale). Both brothers
had normal distal strength, as they were able to walk on
both their toes and heels, and did not have cardiac or respi-
ratory involvement. Muscle MRI performed in patient II.2
when he was 42 years old showed bilateral adipose substi-
tution of the posterior compartment of the thigh with par-
tial atrophy of the quadriceps and adipose substitution of
the soleus muscle (Fig. 5B).3.3. Patients III.1 and III.2
Patient III.1 was a 45-year-old man who presented at
28 years of age with fatigability and cramps. Over the fol-
lowing years, the patient developed pelvic girdle weakness.
He underwent three muscle biopsies, at 28, 41, and 42 years
of age; all of the biopsies showed myopathic changes with
increased connective tissue, nuclear centralisation, andge (A and B) and 43 years of age (C and D). The ﬁrst study demonstrated
gressive involvement of the quadriceps femoris, gastrocnemius, and soleus
ing bilateral adipose substitution of the posterior compartment of the thigh
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analysis showed altered dystrophin expression, especially
with antibodies directed at the N-terminal domain. Molec-
ular analysis of dystrophin with Multiplex-PCR and
MLPA did not reveal any mutations. Muscle CT at
43 years of age demonstrated adipose inﬁltration, mainly
in the posterior thigh compartment and quadriceps.
At the neurological examination, the patient presented
calf pseudohypertrophy, quadriceps atrophy, and proximal
weakness. Cardiac and respiratory evaluations showed a
normal pattern. ANO5 sequencing revealed the presence
of the common c.191dupA mutation, as well as the novel
missense substitution in exon 21, c.2516T>G p.Met839Arg
(Fig. 6C) in the transmembrane domain (Fig. 6E).
Molecular analysis was extended to the other members
of the pedigree. The patient had three sisters (Fig. 2C),
one of whom (patient III.2) carried the same compound
heterozygous mutations and had mild hyperCKemia (3-
fold) without abnormalities at neurological examination
and with no referred weakness. Among the other two sis-
ters, one carried the heterozygous c.191dupA mutation,
and the other had a wild-type genotype. The mother har-
boured the heterozygous c.2516T>G substitution.
3.4. Patient IV
Patient IV was a 50-year-old man born from consan-
guineous Tunisian parents (Fig. 2D). His family history
was negative for neuromuscular disorders, and the
patient’s ﬁrst symptoms started at 47 years of age when
he began to complain of mild proximal weakness with dif-
ﬁculties lifting weights, cramps, and severe myalgia. The
patient also reported some episodes of myoglobinuria,
and his CK levels were mildly increased (2- to 8-fold above
normal values).
At the age of 47 years, the patient underwent muscle
biopsy of the brachial biceps, which showed mild myo-
pathic changes with several nuclear centralisation, few split
ﬁbres, and no connective tissue increase (Fig. 3B). Ultra-
structural analysis demonstrated the presence of basal lam-
ina duplication and separation from the underlying
sarcoplasm (Fig. 3 E and F).
Molecular analysis of ANO5 revealed the presence of a
previously undescribed homozygous missense mutation in
exon 7, c.397A>T (p.Ile133Phe) (Fig. 6D). This mutation
is localised in the N-terminal loop of the protein in a por-
tion of the gene that is well preserved among species
(Fig. 6E). The patient’s sister and brother carried the het-
erozygous c.397A>T mutation and were completely
asymptomatic.
Neuromuscular examination showed predominant lower
limb involvement with severe asymmetric atrophy of both
the quadriceps and the muscles of the posterior compart-
ment (Fig. 4D). Strength was normal except for the quad-
riceps, which had a score of 4 on the MRC scale. The
patient also had mild muscle weakness of the shoulder gir-
dle without atrophy. Distal strength was normal, and thepatient was able to walk on his toes and heels. Tendon
reﬂexes were absent. Overall, the motor impairment was
moderate. The patient did not have cardiac or respiratory
involvement.
3.5. Patients V.1, V.2, and VI
Patients with heterozygous mutations of ANO5 were
characterised by more heterogeneous clinical presentation.
Patients V.1 and V.2 each had a precocious onset, at 3 and
6 years of age, respectively. At their present ages of 46 and
56 years, both patients presented with weakness at the
shoulder girdle and distally in their lower legs. CK levels
are only mildly increased (2-fold) and both patients pre-
sented a respiratory restrictive pattern. Muscle biopsy of
patient V.1 revealed severe dystrophic involvement with
marked connective tissue increase.
Genetic analysis revealed the missense mutation
c.G892A, pGlu.298Lys, localised near the ﬁrst transmem-
brane domain of the protein in a region that is well con-
served among species. Neither ANO5 genomic
sequencing, nor mRNA analysis demonstrated the pres-
ence of a second mutation.
Patient VI was a 21-year-old boy who presented at
6 years of age with cramps and weakness. He did not have
cardiac or respiratory involvement. He currently shows
mild limb girdle weakness with tendon retraction. The
patient’s CK levels ﬂuctuated from normal values up to
12-fold the normal values, and muscle biopsy showed a
severe dystrophic pattern. Sequencing of ANO5 revealed
a missense substitution, c.T1733C (p.Phe578Ser). This
mutation was previously described once in the literature
in association with the common mutation in a patient pre-
senting with late-onset LGMD and mild progression [8].
The father and sister of the patient carried the same muta-
tion and were completely asymptomatic, so we excluded
the possibility that this ANO5 sequence variant acts as a
dominant mutation. Unfortunately, we did not have a mus-
cle sample or blood sample from this patient to analyse
cDNA and search for a second mutation.
4. Discussion
4.1. Incidence of ANO5 mutations and molecular analysis
ANO5 screening of 43 patients (37 families) aﬀected with
LGMD without molecular diagnosis revealed homozygous
or compound heterozygous mutations in six patients
belonging to four independent families. Three patients
(two probands) carried single heterozygous mutations but
were not included in the analysis. These patients exhibit
some peculiar clinical aspects and should probably be con-
sidered carriers of ANO5 mutations. Reporting their
genetic variants may help build a reference database on
the genetic variation of ANO5.
Overall, mutations in ANO5 seem to be responsible for
2% (4/157) of LGMDs diagnosed in our Italian sample
Fig. 6. Molecular analysis. (A–D) In each box, the electropherogram showing the mutation. For missense mutations, the conservation among species. (A)
Family I, (B) Family II, (C) Family III, (D) Family IV. (E) Structure of anoctamin 5 and position of mutations. Mutations in our sample are indicated in
red (missense mutation) and in violet (frameshift mutation). Full circles indicate homozygous or compound heterozygous mutations, empty circles indicate
single heterozygous mutations.
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ope countries, where LGMD2L is considered the third
most common form of LGMD, following LGMD2A and
LGMD2I [8]. In Italy, LGMD is still most commonly
due to mutations in the genes encoding calpain-3, dysferlin,
sarcoglycans, and fukutin-related protein (FKRP).
Among homozygous or compound heterozygous
patients, we found six diﬀerent mutations in ANO5, four
of which are novel (Fig. 1). The common c.191dupA muta-
tion was substantially less frequent than previously
described in the literature and was found in only one
patient, compound heterozygous with a missense mutation.
Conversely, almost all patients from Northern Englandand Germany carry the c.191dupA mutation as a homozy-
gous or compound heterozygous mutation, suggesting a
founder eﬀect. None of our patients carry the c.2272C>T
mutation, which is common in Finnish population.
These data suggest a diﬀerent geographical distribution
of c.191dupA and c.2272C>T mutations. A similar diﬀer-
ent distribution has been observed for the frequency of
LGMD2I [19]; the estimated frequency of FKRP-mutated
LGMD in North-European populations ranges from 16%
to 38%, [20,21] while in Italy ﬁgures of 5% were reported
[19,22]. However, the common FKRP mutation has been
found in Italian and North-European LGMD2I patients
[19–21], while this does not seem to be the case for LGMD
Fig. 7. Relative frequency of diﬀerent forms of LGMD in our sample of
diagnosed patients. LGMD2L accounts for 2% of LGMDs.
942 F. Magri et al. / Neuromuscular Disorders 22 (2012) 934–9432L, making it impossible to use the screening of common
mutation(s) as a ﬁrst approach in the molecular study of
LGMD2L in our population.
Overall, half of our mutations (3/6) were missense. A
review of our data and the literature demonstrates that mis-
sense mutations are mainly localised in the transmembrane
domain or neighbouring regions, suggesting that they inter-
fere with the channel function. However, further studies
are needed to better understand their eﬀect on protein fold-
ing and functioning (Fig. 6E).
4.2. Clinical aspects
Patients with homozygous or compound heterozygous
ANO5 mutations presented with a homogeneous clinical
phenotype that was independent on the kind of mutation
(Table 2). All patients were male except one, and the only
aﬀected woman in the study was still completely asymp-
tomatic at the age of 47 years. Two asymptomatic women
have been described in the literature who, at the ages of
61 and 68 years, presented only with increased CK as a dis-
ease sign [1]. These data suggest a lower incidence in this
gender and the potential presence of protective factors in
females.
Disease onset generally occurred in adulthood at a mean
age of 37.2 ± 7.1 years (range 28–47 years). Symptoms at
onset were mainly myalgia, cramps, and mild weakness;
episodes of myoglobinuria occurred in three of the six
patients. Overall CK values were mildly or signiﬁcantly
increased (values between 2-fold and 32-fold of normal)
and disease progression was slow. All patients were ambu-
lant at the last evaluation (age 47.2 ± 3 years). The major-
ity of patients participated in physical activity at a
competitive level during childhood or in physically
demanding work.
Concerning muscle involvement, patients showed a
peculiar muscle hypotrophy aﬀecting primarily the quadri-
ceps and posterior compartment of the thigh and calf.
Three patients (II.1, II.2, and III.1) exhibited calf pseudo-
hypertrophy (Fig. 4). Muscle weakness usually aﬀected
the quadriceps and hamstrings, preserving the distal mus-
cles. Only two patients presented with mild weakness of
the upper limbs. Cardiac or respiratory involvement was
not described.
4.3. Muscle biopsy features
Muscle biopsy ﬁndings in homozygous and compound
heterozygous patients were also quite similar. All probands
were subjected to at least one muscle biopsy of the brachial
biceps, which generally showed mild myopathic changes
with nuclear centralisations, minimal ﬁbre splitting, and
necroses. Only one patient’s biopsy showed (II.2) a mild
increase in connective tissue (Fig. 3A). Two patients (I
and III.1) underwent a second biopsy of the quadriceps
femoris. In both specimens the histological analysis demon-
strated a more severe pattern, with striking connectivetissue substitution, compared to the biopsy performed on
the biceps brachii. These data suggest that the site of mus-
cle biopsy may inﬂuence the results, with the upper limb
muscles being less clinically aﬀected and, therefore, show-
ing a milder pattern. This diﬀerence possibly could lead
to the exclusion of a diagnosis of muscular dystrophy in
some cases.
Protein expression analysis can also be misleading in
some cases. Two patients (patient III.1 and IV) had a par-
tial reduction of signal in assays with antibodies against
dystrophin. Also, the calpain-3 reduction observed in four
patients seemed to be a secondary deﬁciency, as the cal-
pain-3 gene analysis was negative.
To date, limited ultrastructural data are available. Exist-
ing data show multifocal loss of the sarcolemmal mem-
brane [1,9] without vesicle accumulation, and
reduplication and thickening of the basal lamina mem-
brane [7]. The electron microscopy study performed in
two patients in this study conﬁrmed these data, demon-
strating mild myopathic changes, such as duplication of
the basal lamina, which had thickened with ﬂocculent
aspect, and focal loss of the plasma membrane (Fig. 3C–F).4.4. Muscle imaging
CT and MRI studies of the muscle were performed in
these patients as clinical follow-up studies. The retrospec-
tive analyses of these data provided some insight into the
preferential distribution of tissue damage in LGMD2L.
In our sample, the posterior compartment of the thigh
seemed to be more involved; in later stages also gastrocne-
mius and soleus muscles showed a severe degree of muscle
substitution. Among the muscles of the anterior compart-
ment, only the quadriceps muscles showed changes, with
a patchy pattern (Fig. 5). These data correlate with the
results of clinical evaluations and conﬁrm what has been
previously reported [8,11]. Interestingly, the data available
for patient I trace the evolution of muscle damage over
many years, showing progressive ﬁbro-adipose substitu-
tion, predominantly in the posterior compartment.5. Conclusion
LGMD2L is a rare autosomal recessive form of LGMD
in the Italian population, accounting for only 2% of
F. Magri et al. / Neuromuscular Disorders 22 (2012) 934–943 943diagnosed LGMDs. This form is characterised by high
genetic heterogeneity. However, some common clinical,
morphological, and imaging ﬁndings could be useful in dif-
ferential diagnosis. Further studies involving both ultra-
structural and functional analyses are necessary to better
understand the pathogenesis of this form of muscular
dystrophy.
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